Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Understanding existing research about ambulatory chemotherapy for children and young people
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
Optimising drug treatment for childhood cancer patients
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Understanding how a new drug can selectively fight childhood cancer cells
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Understanding how neuroblastoma and immune cells join forces
Studying how neuroblastoma cells and immune cells interact over time to see how the cancer adapts to treatment.
Making an ‘off-the-shelf’ CAR-T cell treatment for children with solid cancers
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Fighting circular DNA to prevent relapse in acute lymphoblastic leukaemia
Looking at whether medicines that prevent circular DNA replication can help prevent relapse.
Rewriting cancer cell messages to slow down tumour growth
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.